Changing Trends in Industry Funding for Surgical Oncologists

Santamaria-Barria, Juan A.; Stern, Stacey L.; Khader, Adam; Garland-Kledzik, Mary; Scholer, Anthony; Fischer, Trevan; Bilchik, Anton J.

doi:10.1245/s10434-019-07380-1

Cited by 13 publications

(11 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent work has shown that three of the top five companies (Novartis, Amgen, and Merck) provided the majority of funding to surgical oncologists from 2013 to 2017. 26 This large influence of a relative few further highlights a need for transparency.…”

Section: Discussionmentioning

confidence: 99%

“…The top five commercial entities listed were found in 39% of talks with a least one disclosed entity and while not calculated for this study, this frequency may reflect a similar portion of total research support. Recent work has shown that three of the top five companies (Novartis, Amgen, and Merck) provided the majority of funding to surgical oncologists from 2013 to 2017 26 . This large influence of a relative few further highlights a need for transparency.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The disclosure slide—Informative or obligatory, 5 years of SSO Cancer Symposium oral presentations

Merritt

Bouchard

Ford

et al. 2021

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background: Financial disclosure (FD) highlights potential conflicts of interest but is often overlooked at academic conferences.Methods: Retrospective review of 2015-2019 Society of Surgical Oncology Cancer Symposium oral presentation slide and/or verbal FD frequency, duration, and content.Results: Of 963 presentations, 331 (34%) omitted disclosure slide/verbalization. 575 (60%) included a slide, 551 (57%) gave verbal disclosure and 133 (14%) stated relevance. 164 presentations (17%) cited 1 + FD. 2019 had greater median FDs/talk than 2015-2018 (3.50 vs. 2.00; p = .010).

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The disclosure slide—Informative or obligatory, 5 years of SSO Cancer Symposium oral presentations

Merritt

Bouchard

Ford

et al. 2021

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…Other study comparing clinical examination, US and mammography concluded that US was the best single non-invasive method of assessing the extent of nodal involvement. The sensitivity and specificity of US for detection of ALNs have been reported to range from 56% to 73% and 70% to 90%, respectively (Santamaria- Barria et al, 2019).…”

Section: Documentation Of Metastasis In Alnsmentioning

confidence: 99%

“…In other study, they considered the axilla to be positive only if it contained frankly metastatic nodes, visualized as ovoid or lobulated, well demarcated, hypo echoic nodes (>5 mm), and considered to be negative for disease when it was reported to be without any visible adenopathy or to contain echogenic, fat replaced nodes. Previous studies reported that a negative axilla by clinical examination and US after induction chemotherapy still had 48% to 53% chance of being pathologically positive (Santamaria- Barria et al, 2019).…”

Section: Documentation Of Metastasis In Alnsmentioning

confidence: 99%

Evaluation of the Axillary Nodal Status Post Neo-Adjuvant Chemotherapy in Locally Advanced Female Breast Cancer Patients

2022

Al-Azhar Medical Journal

View full text Add to dashboard Cite

Background: Breast cancer is the most common neoplasm among women in the majority of the developed countries, accounting for one-third of newly diagnosed malignancies. Given the efficiency of neo-adjuvant chemotherapy (NACT) in reducing tumor size, it is logical to assume the same response in axilla.Objective: Our propose was to assess axillary lymph nodes (ALNs) response to NACT using clinical, ultrasound (US) or pathological examinations of sentinel lymph node biopsy (SLNB) or ALN dissection (ALND). Patients and methods:This prospective study included 100 female patients with locally advanced breast cancer (LABC) with clinically palpable or US detectable ALNs. True cut biopsy of primary tumor and fine needle aspiration cytology (FNAC) of ALNs were performed before NACT. Clinical and US response of ALNs was assessed. Surgical local control started with SLNB then ALND in all patients followed by appropriate mastectomy procedure. Primary tumor, SLNB and ALND specimens were submitted for pathological examination. Negative SLN by hematoxylin and eosin (H&E) were subjected to immunohistochemical (IHC) section.Results: Clinical, US and pathological complete response (pCR) to NACT were encountered in 47.1%, 33.3% and 31.4% of patients, respectively. The sensitivity of clinical, radiological, SLNB in predicting pCR were 60%, 82.9%, and 94.1% respectively. US was better than clinical examination in response assessment with accuracy of 78.5% versus (vs.) 60.8%, respectively (p<0.001). SLNB was more sensitive than clinical examination in predicting pCR with accuracy of 94.9%. The detection rate of SLN was 76.5%.Conclusions: pCR post NACT is high enough to make axillary conservation worthwhile. US and SLNB can assess and predict nodal response with accepted accuracy rate and SLNB is feasible after NACT.

show abstract

“…4,8 Surgical oncologists appear to geographically concentrate in academic centers. 9,10 Consequently, longer travel times may be required for patients living at a distance from an academic center, unless their municipality has an available community surgical oncologist or a qualified general surgeon. These data are consistent with prior observations.…”

Section: Introductionmentioning

confidence: 99%

Effect of Surgical Oncologist Turnover on Hospital Volume and Treatment Outcomes Among Patients With Upper GI Malignancies

Franko

Franková

2020

JCO Oncology Practice

View full text Add to dashboard Cite

PURPOSE: Lack of surgical expertise may affect cancer care delivery. Here, we examined the impact of surgical oncologist vacancy and turnover in a community cancer center serving a mixed urban and rural population. METHODS: Survival outcomes of patients with potentially resectable esophageal, gastric, and pancreatic carcinomas treated in the index hospital (n = 519) were compared with those of a then-contemporary control group derived from the state-specific SEER registry (n = 3,340). The onboarding period (ie, the period without a surgical oncologist) and early and late periods with a surgical oncologist were defined. RESULTS: At the state level, there was a steady trend of patients who were annually referred (290.4 ± 34.3 patients per year; P < .001) and underwent operation (158.7 ± 18.7 patients per year; P < .001). We observed the absence of an analogous trend in the index hospital ( P = .141). The index hospital diagnosed 12.2% of state cancers of interest during the years with surgical oncologists but only 6.7% of cancers when surgical oncologists were absent ( P = .031). The survival model adjusted for age, stage, and primary disease site comparing the early and late periods demonstrated that being treated in the index hospital did not result in inferior survival (hazard ratio, 1.067; P = .265). CONCLUSION: Loss of surgical oncologists was associated with referral decline and likely out-migration of patients, whereas prompt restoration of surgical oncology services reinstated volumes and preserved survival outcomes.

show abstract

Changing Trends in Industry Funding for Surgical Oncologists

Cited by 13 publications

References 12 publications

The disclosure slide—Informative or obligatory, 5 years of SSO Cancer Symposium oral presentations

The disclosure slide—Informative or obligatory, 5 years of SSO Cancer Symposium oral presentations

Evaluation of the Axillary Nodal Status Post Neo-Adjuvant Chemotherapy in Locally Advanced Female Breast Cancer Patients

Effect of Surgical Oncologist Turnover on Hospital Volume and Treatment Outcomes Among Patients With Upper GI Malignancies

Contact Info

Product

Resources

About